Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ortho-McNeil-Janssen Pharmaceuticals has entered into a five-year collaboration agreement called Transcend with David Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
Subscribe to our email newsletter
The agreement is intended to foster oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, and profiles of the tumor microenvironment.
The two entities said that a Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees will jointly review and select proposals from MIT researchers for funding. Projects will involve interdisciplinary faculty, students and staff to address oncology solutions.
William Hait, global therapeutic area head, oncology at Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Janssen, said: “The Transcend program embodies our external approach to research. By collaborating with academic institutions and colleagues at the interface of engineering and biology, we’re able to bring together the best scientific minds in industry and academia to meet unmet medical needs in patients with cancer.”
“The visiting scientist aspect of the program is designed to promote interactive exchange between our organizations at the bench. We believe both organisations will benefit from our scientists’ experience of learning, interacting and innovating together.”